Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-26T17:00:32.465Z Has data issue: false hasContentIssue false
  • English
  • Français

Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study

Published online by Cambridge University Press:  07 November 2014

Richard Weisler ,
J. Mark Joyce ,
Lora McGill ,
Arthur Lazarus ,
Johan Szamosi ,
Hans Eriksson  and
Moonstone Study Group
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD).

Method: This was an 8-week (6-week randomized-phase; 2-week drug-discontinuation/tapering phase), double-blind, parallel-group, placebo-controlled study. The primary outcome measure was Montgomery-Åsberg Depression Rating Scale (MADRS) total score randomization-to-Week 6 change. Other assessments included the Hamilton Rating Scale for Depression, the Hamilton Rating Scale for Anxiety, and adverse events (AEs).

Results: 723 patients were randomized: 182, 178, 179, and 184 to quetiapine XR 50, 150, 300 mg/day, and placebo, respectively. At Week 6, significant reductions occurred in MADRS score with quetiapine XR 50 mg/day (−13.56; P<.05), 150 mg/day (−14.50; P<.01) and 300 mg/day (−14.18; P<.01) versus placebo (−11.07); at Day 4, reductions for quetiapine XR (titrated to 50 or 150 mg/day according to dose group) versus placebo (−2.9) were: −4.7 (P<.01), −5.2 (P<.001), and −5.1 (P<.001), respectively. At endpoint, MADRS response (≥50% reduction in score) was 42.7% (P<.01), 51.2% (P<.001), and 44.9% (P≤.001) for quetiapine XR 50, 150, and 300 mg/day, respectively; 30.3% for placebo. Overall, quetiapine XR 150 mg/day provided consistently more positive secondary efficacy results than 50 mg/day and 300 mg/day versus placebo. The most common AEs in quetiapine XR-treated patients were dry mouth, sedation, somnolence, headache, and dizziness.

Conclusion: In patients with MDD, quetiapine XR monotherapy (50/150/300 mg/day) is effective in reducing depressive symptoms, with improvement from Day 4 onwards. Safety and tolerability were consistent with the known profile of quetiapine.

Type
Original Research
Information
CNS Spectrums , Volume 14 , Issue 6 , June 2009 , pp. 299 - 313
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Rush, AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68(Suppl 10):8–10.Google Scholar
2.Nemeroff, CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68 (Suppl 8):17–25.Google Scholar
3.Trivedi, MH, Hollander, E, Nutt, D, Blier, P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008;69:246–258.Google Scholar
4.Crown, WH, Finkelstein, S, Berndt, ER, et al.The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963–971.Google Scholar
5.Trivedi, MH. Major depressive disorder: remission of associated symptoms. J Clin Psychiatry. 2006;67(Suppl 6):27–32.Google ScholarPubMed
6. Hospital stays related to mental health, 2006. Available at: http://www.hcupus.ahrq.gov/reports/statbriefs/sb62.pdf. Accessed November 7, 2008.Google Scholar
7.Hansen, RA, Gartlehner, G, Lohr, KN, Gaynes, BN, Carey, TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143:415–426.Google Scholar
8. Suicidal Thoughts, Suicide Attempts, Major Depressive Episode, and Substance Use among Adults. Available at: http://www.oas.samhsa.gov/2k6/suicide/suicide. pdf. Accessed August 20, 2008.Google Scholar
9.Jick, H, Kaye, JA, Jick, SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338–343.Google Scholar
10.Mulder, RT, Joyce, PR, Frampton, CM, Luty, SE. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr Scand. 2008;118:116–122.Google Scholar
11.Machado-Vieira, R, Salvadore, G, Luckenbaugh, DA, Manji, HK, Zarate, CA. Rapid Onset of Antidepressant Action: A New Paradigm in the Research and Treatment of Major Depressive Disorder. J Clin Psychiatry. 2008;69:946–958.Google Scholar
12.Prince, M, Patel, V, Saxena, S, et al.No health without mental health. Lancet. 2007;370:859–877.Google Scholar
13.Mathers, CD, Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.CrossRefGoogle ScholarPubMed
14.Greenberg, PE, Kessler, RC, Bimbaum, HG, et al.The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465–1475.Google Scholar
15.Mullen, J, Jibson, MD, Sweitzer, D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther. 2001;23:1839–1854.Google Scholar
16.Calabrese, JR, Keck, PE Jr, Macfadden, W, et al.A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351–1360.Google Scholar
17.Thase, ME, Macfadden, W, Weisler, RH, et al.Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–609.Google Scholar
18.Weisler, RH, Calabrese, JR, Thase, ME, et al.Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry. 2008;69:769–782.Google Scholar
19.McElroy, S, Young, AH, Carlsson, A, et al.A double-blind, placebo-controlled study with acute and continuation phase of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II) [abstract]. Bipolar Disord. 2008;10(Suppl 1):59.Google Scholar
20.Young, AH, McElroy, S, Chang, W, Olausson, B, Paulsson, B, Brecher, M. A doubleblind, placebo-controlled study with acute and continuation phase of quetiapine and lithium in adults with bipolar depression (EMBOLDEN I) [abstract]. Int J Neuropsychopharmacol. 2008;11:187.Google Scholar
21.Weisler, RH, Nolen, WA, Neijber, A, Hellqvist, A, Paulsson, B. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Poster presented at: the 60th Institute on Psychiatric Services; October 2-5, 2008; Chicago, IL.Google Scholar
22.Bauer, M, Pretorius, H, Constant, E, Earley, W, Szamosi, J, Brecher, M. Extended release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540–549.Google Scholar
23.El-Khalili, N, Joyce, M, Atkinson, S, Buynak, R, Datto, C, Lindgren, P, Eriksson, H, Brecher, M. Adjunctive extended release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response. Poster presented at: the 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC.Google Scholar
24.McIntyre, A, Gendron, A, McIntyre, A. Quetiapine adjunct to selective serotonin reuptake inhibitors (SSRIs) or venlafaxine in patients with major depression, comorbid anxiety and residual depressive symptoms: a randomized, placebo controlled pilot study. Depress Anxiety. 2007;24:487–494.Google Scholar
25.Datto, C, Berggren, L, Patel, J, Eriksson, HA. Self-Reported Sedation Profile of Immediate-Release Quetiapine Fumarate Compared With Extended-Release Quetiapine Fumarate During Dose Initiation: A Randomized, Double-Blind, Crossover Study in Healthy Adult Subjects. Clin Ther. 2009;31:492–502.Google Scholar
26.Figueroa, C, Brecher, M, Hamer-Maansson, JE, Winter, H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:199–204.Google Scholar
27. Seroquel (quetiapine fumarate) US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/seroquel.pdf. Accessed May 1, 2009.Google Scholar
28.Cutler, A, Montgomery, S, Feifel, D, Lazarus, A, Åström, M, Brecher, M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry. 2009;70:526–539.Google Scholar
29.Earley, W, McIntyre, A, Wang, G, Raines, S, Eriksson, HA. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) [abstract]. Int J Psychiatry Clin Pract. 2008;12(Suppl 4):332.Google Scholar
30.El-Khalili, N, Banov, M, Bortnick, B, Adson, D, Datto, C, Raines, S, Earley, W, Brecher, M. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder (MDD): a randomized, placebo-controlled clinical trial (Study 003). Poster presented at: the 63rd Annual Society of Biological Psychiatry; May 1-3, 2008; Washington, DC.Google Scholar
31.Katila, H, Mezhebovsky, I, Mulroy, A, Berggren, L, Datto, C, Eriksson, HA, Olausson, B. Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD) [abstract]. Int J Psychiatr Clin Pract. 2008; 12(Suppl 4):337.Google Scholar
32.Datto, C, Lam, RW, Lepola, U, Sweitzer, D, Eriksson, HA. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment in patients with MDD [abstract]. Eur Neuropsychopharmacol. 2008;18(Suppl 4):S377–S378.Google Scholar
33.Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
34.Sheehan, DV, Lecrubier, Y, Sheehan, KH, et al.The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.Google Scholar
35.Michelson, D, Fava, M, Amsterdam, J, et al.Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363–368.Google Scholar
36.Rosenbaum, JF, Fava, M, Hoog, SL, Ascroft, RC, Krebs, WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77–87.CrossRefGoogle ScholarPubMed
37.Pinson, L, Gray, GE. Psychopharmacology: number needed to treat: an underused measure of treatment effect. Psychiatr Serv. 2003;54:145–6, 154.Google Scholar
38.Dmitrienko, A, Wiens, BL, Tamhane, AC, Wang, X. Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med. 2007;26:2465–2478.Google Scholar
39.Bernert, RA, Joiner, TE. Sleep disturbances and suicide risk: A review of the literature. Neuropsychiatr Dis Treat. 2007;3:735–743.Google Scholar
40.Wojnar, M, Ilgen, MA, Wojnar, J, McCammon, RJ, Valenstein, M, Brower, KJ. Sleep problems and suicidality in the National Comorbidity Survey Replication. J Psychiatr Res. 2009;43:526–531.Google Scholar
41.Papakostas, GI, Nelson, JC, Kasper, S, Moller, HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2008;18:122–127.Google Scholar
42.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.Google Scholar
43.Jensen, NH, Rodriguiz, RM, Caron, MG, Wetsel, WC, Rothman, RB, Roth, BL. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33:2303–2312.Google Scholar
44.Nyberg, S, Takano, A, Grimm, S, Gulyas, B, McCarthy, D, Lee, C, Goldstein, J, Halldin, C, Farde, L. PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates. Eur Neuropsychopharmacol. 2007;17 (Suppl 4):S254–S255.Google Scholar
45.Galper, DI, Trivedi, MH, Barlow, CE, Dunn, AL, Kampert, JB. Inverse association between physical inactivity and mental health in men and women. Med Sci Sports Exerc. 2006;38:173–178.CrossRefGoogle ScholarPubMed
46.Gao, K, Kemp, DE, Ganocy, SJ, Gajwani, P, Xia, G, Calabrese, JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:203–209.CrossRefGoogle ScholarPubMed
47.Leo, RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449–454.Google Scholar
48.Wagstaff, AJ, Cheer, SM, Matheson, AJ, Ormrod, D, Goa, KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62:655–703.Google Scholar
49.Hewett, K, Chrzanowski, W, Schmitz, M, et al.Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2008 Jul 17. [Epub ahead of print].Google ScholarPubMed
50.Clayton, A, Kornstein, S, Prakash, A, Mallinckrodt, C, Wohlreich, M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4:917–929.Google Scholar